Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release

Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release

To the Editor: A recent article by Baron et al. reports the results of a clinical trial (CT) to compare the effectiveness of tapentadol with oxycodone/ naloxone (Ox/Nal) for the treatment of chronic low back pain of neuropathic origin. This study is a remarkable attempt to progress in this area. We argue, however, that it contains several drawbacks that leave open ground for further trials with...

Tapentadol Prolonged Release as Used in Clinical Practice in Patients with Severe Chronic Tumor Pain

Objective: This subgroup analysis of a non-interventional study that included general practitioners and internists, assessed efficacy and safety of tapentadol prolonged release (Palexia® retard) as used in routine clinical practice in Germany for the treatment of severe chronic tumor pain. Study design: Data of all patients in the study cohort who were exclusively diagnosed with ‘tumor pain’ (n...

Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.

BACKGROUND Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. AIM To compare the efficacy and safety of once- (OD) vs. twice- (BD) daily prolonged-release mesalazine (Pentasa, Ferring, Saint-Prex, Switzerland) for active mild-to-moderate UC in a non-inferiority study. METHODS Eligible patients (...

Circadin Prolonged Release Tablets

Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.

BACKGROUND Tapentadol prolonged release (PR) is effective and well tolerated for chronic osteoarthritis, low back, and diabetic peripheral neuropathic pain. OBJECTIVES To evaluate the efficacy and tolerability of tapentadol PR compared with placebo and morphine controlled release (CR) for managing moderate to severe chronic malignant tumor-related pain. STUDY DESIGN Randomized-withdrawal, p...